Priya Rastogi was named chief executive officer of the National Surgical Adjuvant Breast and Bowel Project Foundation, effective July 1. In addition to this new role, she will continue serving as medical director of NSABP.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.Â
